glp-1 for prediabetes Prevention: Using Drugs Like Zepbound for Pre-Diabetes or Metabolic Risk -What Does Research Say? GLP-1 for Diabetes vs GLP-1
Description
A meta-analysis published in 2024 involving data from multiple randomized controlled trials found that patients taking GLP-1 receptor agonists had a statistically significant increased risk of developing DVT compared to control groups
and presentation should still be thoughtfully crafted
Timeline of the coverage reversal The announcements clustered in the second half of 2025
Insights on Glicentin, a Promising Peptide of the Proglucagon Family
Royal Pharmaceutical Society
